Trump Rejects Medicare Coverage for Obesity Drugs
Tap title to read story
0:00 / 0:30
President Trump rejected a Biden administration plan to have Medicare cover expensive obesity drugs like Wegovy and Mounjaro. The proposal, which could have cost taxpayers $35 billion over nine years, aimed to provide access to millions. While Medicare may reconsider coverage later, the rejection caused shares of Eli Lilly and Novo Nordisk to fall. Currently, many patients cannot afford these drugs, which cost roughly $1,000 before insurance.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
